Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
Study Details
Study Description
Brief Summary
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
This is a phase II trial designed to provide a transplant option for patients with rare poor-prognosis cancers. The protocol is only open to patients with metastatic or relapsed cancers for whom the probability of remaining free of progressive disease for one year after being brought into remission is < 25%. Patients eligible for this study have been diagnosed with a form of cancer that leads to death more than 75% of the time when treated with standard therapy doses of chemotherapy and/ or radiation therapy. Under this treatment intensification protocol the expectation is that the one year progression-free survival for this group of patients will rise to 40%. Patients eligible for this protocol will be followed for one year post-transplant. Patients alive and free of progressive disease at the end of this period will be considered successes.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Myeloablative Chemotherapy with Stem Cell Rescue Myeloablative Chemotherapy, followed by stem cell rescue |
Procedure: Myeloablative Chemotherapy
High dose chemotherapy (carboplatin and thiotepa) transplant rescue
Procedure: Stem Cell Rescue
autologous stem cell transplantation
|
Outcome Measures
Primary Outcome Measures
- Percent of Participants With Progression Free Survival at 1 Year [1 year post transplant]
The primary outcome measure for this study was to improve the long-term disease-free survival of patients with rare cancers at high risk for lethal relapse.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients must be ineligible for other IRB-approved myeloablative regimens, be 21 years old or younger, and must have a histologically-confirmed Wilms' tumor, liver cancer, recurrent brain tumor of childhood, nasopharyngeal carcinoma, fibrosarcoma, desmoplastic small round cell tumor, germ cell tumor or other small round cell tumor, which:
-
is metastatic and has < 25% cure rate with conventional treatment; or
-
progressed after prior chemotherapy and has < 25% salvage rate with non-myeloablative therapies.
- Disease status: Within 3 weeks of initiation of this protocol, patients must:
-
be in a complete or good partial remission (section 7.4); or
-
have a "chemosensitive" tumor, which is defined as a > 50% decrease in at least one measurable tumor parameter attributable to prior chemotherapy, without evidence of progressive disease by any other parameter.
- Prior chemotherapy: Before entry to this protocol, patients must have derived maximal benefit from conventional, i.e., nonmyeloablative, doses of combination chemotherapy. Conventional therapy should be continued until either a complete remission is achieved, no further benefit from non-myeloablative dosing can be appreciated, or toxicity from conventional therapy is perceived as limiting in the absence of stem cell rescue. The cancer must be proven to be sensitive to alkylating agents. This means that, in addition to, or as part of, the appropriate chemotherapy protocol for the specific cancer in question, all patients must have received and responded to a minimum of:
-
2 courses of high-dose cyclophosphamide, totaling > 4200 mg/m2; or
-
courses of high-dose ifosfamide totaling > 12 gm/m2.
-
1 course of "a)" above, plus 1 course of 'b)" above.
-
Equivalent high dose alkylating agents as described in 3.3 a, b, and c.
-
Patients must have adequate renal hepatic, and cardiac function (sections 4.4-4.6).
-
Patients must meet at least one of the following stem cell requirements (Peripheral blood collection is to be preferred when available as an option):
-
Harvested bone marrow must contain 1 x 108 nucleated cells per kg of body weight, or,
-
Peripheral blood collection should include at least 2 x 106 CD34+ cells/kg.
- Informed consent must be signed indicating patient and/or parental awareness of the investigational nature of this program
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | The University of Michigan | Ann Arbor | Michigan | United States | 48109 |
Sponsors and Collaborators
- University of Michigan Rogel Cancer Center
Investigators
- Principal Investigator: John E. Levine, MS MD, The Univeristy of Michigan
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UMCC 9626
- IRB 1996-195
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Myeloablative Chemotherapy With Stem Cell Rescue |
---|---|
Arm/Group Description | Myeloablative Chemotherapy: High dose chemotherapy (carboplatin and thiotepa) transplant rescue Stem Cell Rescue: autologous stem cell transplantation |
Period Title: Overall Study | |
STARTED | 25 |
COMPLETED | 25 |
NOT COMPLETED | 0 |
Baseline Characteristics
Arm/Group Title | Myeloablative Chemotherapy With Stem Cell Rescue |
---|---|
Arm/Group Description | Myeloablative Chemotherapy: High dose chemotherapy (carboplatin and thiotepa) transplant rescue Stem Cell Rescue: autologous stem cell transplantation |
Overall Participants | 25 |
Age (years) [Mean (Full Range) ] | |
Mean (Full Range) [years] |
6
|
Sex: Female, Male (Count of Participants) | |
Female |
12
48%
|
Male |
13
52%
|
Outcome Measures
Title | Percent of Participants With Progression Free Survival at 1 Year |
---|---|
Description | The primary outcome measure for this study was to improve the long-term disease-free survival of patients with rare cancers at high risk for lethal relapse. |
Time Frame | 1 year post transplant |
Outcome Measure Data
Analysis Population Description |
---|
[Not Specified] |
Arm/Group Title | Myeloablative Chemotherapy With Stem Cell Rescue |
---|---|
Arm/Group Description | Myeloablative Chemotherapy: High dose chemotherapy (carboplatin and thiotepa) transplant rescue Stem Cell Rescue: autologous stem cell transplantation |
Measure Participants | 25 |
Number [percentage of participants] |
58
232%
|
Adverse Events
Time Frame | ||
---|---|---|
Adverse Event Reporting Description | ||
Arm/Group Title | Myeloablative Chemotherapy With Stem Cell Rescue | |
Arm/Group Description | Myeloablative Chemotherapy: High dose chemotherapy (carboplatin and thiotepa) transplant rescue Stem Cell Rescue: autologous stem cell transplantation | |
All Cause Mortality |
||
Myeloablative Chemotherapy With Stem Cell Rescue | ||
Affected / at Risk (%) | # Events | |
Total | / (NaN) | |
Serious Adverse Events |
||
Myeloablative Chemotherapy With Stem Cell Rescue | ||
Affected / at Risk (%) | # Events | |
Total | 19/25 (76%) | |
Blood and lymphatic system disorders | ||
Neutropenic Fever | 2/25 (8%) | |
Cardiac disorders | ||
Hypertension | 1/25 (4%) | |
Gastrointestinal disorders | ||
Mucocitis | 10/25 (40%) | |
Diarrhea | 2/25 (8%) | |
Enterocolitis | 1/25 (4%) | |
General disorders | ||
Death | 2/25 (8%) | |
Fever | 6/25 (24%) | |
Graft Failure | 1/25 (4%) | |
Immune system disorders | ||
Febrile Transfusion Reaction | 1/25 (4%) | |
Infections and infestations | ||
Infection | 11/25 (44%) | |
Investigations | ||
Thrombocytopenia | 1/25 (4%) | |
Metabolism and nutrition disorders | ||
Hypokalemia | 2/25 (8%) | |
Hypcalcemia | 2/25 (8%) | |
Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||
Disease Relapse | 1/25 (4%) | |
Renal and urinary disorders | ||
Renal Failure | 1/25 (4%) | |
Respiratory, thoracic and mediastinal disorders | ||
Epistaxis | 1/25 (4%) | |
Tachypnea | 2/25 (8%) | |
Hypoxia | 1/25 (4%) | |
Skin and subcutaneous tissue disorders | ||
Dermatitis | 1/25 (4%) | |
Other (Not Including Serious) Adverse Events |
||
Myeloablative Chemotherapy With Stem Cell Rescue | ||
Affected / at Risk (%) | # Events | |
Total | 12/25 (48%) | |
Ear and labyrinth disorders | ||
Hearing Loss | 2/25 (8%) | |
Gastrointestinal disorders | ||
Esophagitis | 2/25 (8%) | |
Mucocitis | 2/25 (8%) | |
Investigations | ||
ALK | 3/25 (12%) | |
AST | 6/25 (24%) | |
ALT | 5/25 (20%) | |
Metabolism and nutrition disorders | ||
Hypokalemia | 8/25 (32%) | |
Hyperglycemia | 4/25 (16%) | |
Hypocalcemia | 5/25 (20%) | |
Hypomagnesemia | 3/25 (12%) | |
Hypernatremia | 2/25 (8%) | |
Hypercalcemia | 2/25 (8%) | |
Hypoalbuminemia | 4/25 (16%) | |
Hyperkalemia | 3/25 (12%) | |
Hyponatremia | 2/25 (8%) |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Dr. John E. Levine, MD |
---|---|
Organization | University of Michigan Cancer Center |
Phone | 734-936-8456 |
jelevine@umich.edu |
- UMCC 9626
- IRB 1996-195